Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2025
Reporting Period: Fiscal Year ended December 31, 2023 (refiled)
Primary Event: Refiling of Consolidated Financial Statements to reflect a 1-for-10 reverse stock split effective July 15, 2024.
Key Financial Metrics
This filing serves as a restatement of previously filed data and does not contain new operational financial results for the current period. The document incorporates by reference the Consolidated Balance Sheets, Statements of Operations, and Cash Flows originally filed in the Form S-1 on December 12, 2024.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide specific numerical values for these metrics; they are contained in the referenced exhibits.
- Debt and Liquidity: Specific figures are not disclosed in the text of this 8-K; refer to the incorporated Consolidated Balance Sheets.
- Stock Structure: Common stock par value is $0.0001 per share. All share and per-share data in the refiled statements have been adjusted for the 1-for-10 reverse stock split.
Material Changes Versus Prior Period
The only material change disclosed in this filing is the retroactive adjustment of the Fiscal Year 2023 financial statements to account for the 1-for-10 reverse stock split. The filing explicitly states that all other information in the 2023 Annual Report remains unchanged and that the exhibits do not reflect events occurring after the original 2023 Annual Report filing.
Guidance, Outlook, and Risks
Management Commentary: The filing is administrative in nature, intended solely to update historical financial statements for the reverse stock split. No new management commentary, forward-looking guidance, or outlook is provided in this document.
Risks and Contingencies: No new risks or contingencies are disclosed. The filing notes that the information should be read in conjunction with the 2023 Annual Report.
Investor Verification Checklist
- Verify the adjusted share count and per-share metrics in the refiled 2023 financial statements to ensure consistency with the 1-for-10 reverse stock split.
- Review the referenced Form S-1 (filed December 12, 2024) for the actual numerical values of revenue, cash flow, and liquidity, as they are not listed in this 8-K text.
- Confirm that no other operational changes or events have occurred between the original 2023 filing and this January 2025 restatement.